Japanese Journal of Radiology

, Volume 37, Issue 12, pp 799–807 | Cite as

13N-NH3 PET/CT in oncological disease

  • Domenico AlbanoEmail author
  • Raffaele Giubbini
  • Francesco Bertagna


13N-Ammonia (13N-NH3) is widely used positron emission tomography/computed tomography (PET/CT) radiotracer for the measurement of myocardial blood perfusion; the possible role of 13N-NH3 PET or PET/CT in oncological disease is not yet clear. Aim of this review is to evaluate the diagnostic performances of 13N-NH3 PET in this field. A comprehensive computer literature search of the PubMed/MEDLINE, Scopus, and Embase databases was conducted including articles up to June 2019. Eighteen articles were finally included in the review. From the analyses of the selected studies, the following main findings could be drawn: (1) 13N-NH3 PET is useful in discriminating between gliomas and non-neoplastic brain lesions, and among gliomas between high-grade and low-grade gliomas; (2) 13N-NH3 PET have better diagnostic performance than 18F-FDG in studying gliomas; (3) a combination of 13N-NH3 PET and 18F-FDG PET may be useful to differentiate between several cerebral lesions (gliomas, cerebral lymphoma, meningioma); (4) only preliminary results about the positive impact in liver and prostate cancer.


13N-NH3 PET/CT Oncological disease Review Glioma 


Compliance with ethical standards

Conflict of interest

The authors declare they have no conflict of interest.


  1. 1.
    Giubbini R, Peli A, Milan E, Sciagrà R, Camoni L, Albano D, et al. Comparison between the summed difference score and myocardial blood flow measured by 13N-ammonia. J Nucl Cardiol. 2018;25:1621–8.CrossRefGoogle Scholar
  2. 2.
    Sciagrà R, Milan E, Giubbini R, Kunik T, Di Dato R, Gallo L, et al. Sub-endocardial and sub-epicardial measurement of myocardial blood flow using 13NH3 PET in man. J Nucl Cardiol 2018.
  3. 3.
    Stabin MG. Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk. J Nucl Med. 2008;49:1555–633.CrossRefGoogle Scholar
  4. 4.
    Maddahi J, Packard RR. Cardiac PET perfusion tracers: current status and future directions. SeminNucl Med. 2014;44:333–43.Google Scholar
  5. 5.
    Monahan WG, Tilbury RS, Laughlin JS. Uptake of 13 N-labeled ammonia. J Nucl Med. 1972;13:274–7.PubMedGoogle Scholar
  6. 6.
    Cooper AJ. 13N as a tracer for studying glutamate metabolism. NeurochemInt. 2011;59:456–64.CrossRefGoogle Scholar
  7. 7.
    Rauch B, Helus F, Grunze M, Braunwell E, Mall G, Hasselbach W, Kübler W. Kinetics of 13N-ammonia uptake in myocardial single cells indicating potential limitations in its applicability as a marker of myocardial blood flow. Circulation. 1985;71:387–93.CrossRefGoogle Scholar
  8. 8.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.CrossRefGoogle Scholar
  9. 9.
    Cooper AJ, McDonald JM, Gelbard AS, Gledhill RF, Duffy TE. The metabolic fate of 13N-labeled ammonia in rat brain. J Biol Chem 1979;254:4982–92.Google Scholar
  10. 10.
    Schelstraete K, Simons M, Deman J, Vermeulen FL, Slegers G, Vandecasteele C, et al. Uptake of 13N-ammonia by human tumours as studied by positron emission tomography. Br J Radiol. 1982;55:797–804.CrossRefGoogle Scholar
  11. 11.
    Schelstraete K, Deman J, Vermeulen FL, Strijckmans K, Vandecasteele C, Slegers G, De Schryver A. Kinetics of 13N-ammonia incorporation in human tumours. Nucl Med Comm. 1985;6:461–70.CrossRefGoogle Scholar
  12. 12.
    Xiangsong Z, Changhong L, Weian C, Dong Z. PET imaging of cerebral astrocytoma with 13N-ammonia. J Neuro-Oncol. 2006;78:145–51.CrossRefGoogle Scholar
  13. 13.
    Xiangsong Z, Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol. 2007;82:305–11.CrossRefGoogle Scholar
  14. 14.
    Yi C, Shi X, Zhang X, Luo G, Zhang B, Zhang X. The role of 13N-ammonia in the differential diagnosis of gliomas and brain inflammatory lesions. Ann Nucl Med. 2019;33:61–7.CrossRefGoogle Scholar
  15. 15.
    Xiangsong ZWC, Weian C, Dianchao Y, Xiaoyan W, Zhifeng C, Xiongchong S. Usefulness of (13)N-NH (3) PET in the evaluation of brain lesions that are hypometabolic on (18)F-FDG PET. J Neuro-Oncol. 2011;105:103–7.CrossRefGoogle Scholar
  16. 16.
    Shi X, Liu Y, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med. 2013;38:522–6.CrossRefGoogle Scholar
  17. 17.
    He Q, Zhang L, Zhang B, Shi X, Yi C, Zhang X. Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18Ffluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma. BMC Cancer. 2019;19:332.CrossRefGoogle Scholar
  18. 18.
    Khangemban BC, Karunanithi S, Sharma P, Kc SS, Kumar R, Julka PK, et al. Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT. Neuroradiology. 2014;56:893–902.CrossRefGoogle Scholar
  19. 19.
    Mattakarottu JJ, Pandit AG, Jora C, Mudalsha R, Sharma A, Pathak HC. Comparative study of 18F-DOPA, 13N-Ammonia and F18-FDG PET/CT in primary brain tumors. Indian J Nucl Med. 2011;26:139–43.CrossRefGoogle Scholar
  20. 20.
    Jora C, Mattakarottu JJ, Aniruddha PG, Mudalsha R, Singh DK, Pathak HC, et al. Comparative evaluation of 18F-FDOPA, 13N-AMMONIA, 18F-FDG PET/CT and MRI in primary brain tumors—a pilot study. Indian J Nucl Med 2011;26:78–81.CrossRefGoogle Scholar
  21. 21.
    Xiangsong Z, Xinjian W, Yong Z, Weian C. 13N-NH3: a selective contrast-enhancing tracer for brain tumor. Nucl Med Comm. 2008;29:1052–8.CrossRefGoogle Scholar
  22. 22.
    Khangembam BC, Sharma P, Karunanithi S, Singhal A, Das CJ, Kumar P, et al. 13N ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast enhanced MRI. Nucl Med Commun. 2013;34:1046–54.CrossRefGoogle Scholar
  23. 23.
    Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med. 2013;38:98–102.CrossRefGoogle Scholar
  24. 24.
    Shi X, Yi C, Wang X, Zhang B, Chen Z, Tang G, Zhang X. 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med. 2015;40:195–9.CrossRefGoogle Scholar
  25. 25.
    Xiangsong Z, Xingchong S, Chang Y, Xiaoyan W, Zhifeng C. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med. 2011;36:1003–6.CrossRefGoogle Scholar
  26. 26.
    Shi X, Zhang X, Yi C, Liu Y, He Q. [13N]Ammonia positron emission tomographic/computed tomographic imaging targeting glutamine synthetase expression in prostate cancer. Mol Imaging. 2014;13:1–10.Google Scholar
  27. 27.
    Yi C, Tu D, Shi X, Zhang X, Luo G, He Q, Zhang X. The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer. Nucl Med Commun. 2016;37:239–46.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Shibata T, Yamamoto K, Hayashi N, Yonekura Y, Nagara T, Saji H, et al. Dynamic positron emission tomography with 13N-ammonia in liver tumors. Eur J Nucl Med. 1988;14:607–11.CrossRefGoogle Scholar
  29. 29.
    Shyn PB, Casadaban LC, Sainani NI, Sadow CA, Bunch PM, Levesuq VM, et al. Intraprocedural ablation margin assessment by using ammonia perfusion PET during FDG PET/CT–guided liver tumor ablation: a pilot study. Radiology. 2018;288:138–45.CrossRefGoogle Scholar
  30. 30.
    Albano D, Bertoli M, Battistotti M, Rodella C, Statuto M, Giubbini R, Bertagna F. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Ann Nucl Med. 2018;32:532–41.CrossRefGoogle Scholar
  31. 31.
    Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino Acid transporters in cancer and their relevance to ‘‘glutamine addiction’’: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75:1782–8.CrossRefGoogle Scholar
  32. 32.
    Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103:498–507.CrossRefGoogle Scholar
  33. 33.
    Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012;33:69–766.CrossRefGoogle Scholar
  34. 34.
    Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger MD. Characterization of angiogenesis and microcirculation of high gradeglioma: an intravitalmultifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab. 1998;18:510–20.CrossRefGoogle Scholar
  35. 35.
    Albano D, Bertoli M, Ferro P, Fallanca F, Gianolli L, Picchio M, et al. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentricexperience. Eur J Nucl Med 2017;44:589–597.CrossRefGoogle Scholar
  36. 36.
    Albano D, Bosio G, Giubbini R, Bertagna F. 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. Leuk Lymphoma. 2017;58:2328–34.CrossRefGoogle Scholar
  37. 37.
    Akimoto J. Immunohistochemical study of glutamine synthetase expression in normal human brain and intracranial tumors. No ToShinkei. 1993;45:362–8.Google Scholar
  38. 38.
    Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study. Mol Pharm. 2014;11:3923–9.CrossRefGoogle Scholar
  39. 39.
    Albano D, Bosio G, Bertoli M, Giubbini R, Bertagna F. 18F-FDG PET/CT in primary brain lymphoma. J Neurooncol. 2018;136:577–83.CrossRefGoogle Scholar

Copyright information

© Japan Radiological Society 2019

Authors and Affiliations

  1. 1.Nuclear MedicineUniversity of Brescia and Spedali Civili BresciaBresciaItaly

Personalised recommendations